Phase I/II Trial of Ipilimumab (Immunotherapy) and Hypofractionated Stereotatic Radiation Therapy in Patients with Advanced Solid Malignancies
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 24 May 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary)
- Indications Adrenal cancer; Liver cancer; Lung cancer
- Focus Adverse reactions
- 21 May 2019 Planned End Date changed from 1 Aug 2019 to 1 Aug 2020.
- 31 Aug 2018 Biomarkers information updated
- 11 May 2018 Status changed from recruiting to active, no longer recruiting.